<DOC>
	<DOCNO>NCT00501111</DOCNO>
	<brief_summary>The purpose study demonstrate AZD3480 improve cognition patient mild moderate Alzheimer 's disease , assess safety tolerability ZAD3480 define optimal dose ( ) use future trial .</brief_summary>
	<brief_title>Proof Concept Study Cognitive Improvement Patients With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Provision inform consent patient caregiver Clinical prognosis probable Alzheimer 's disease Patient must caregiver visit patient least three time weekly Significant neurologic disease dementia Alzheimer 's disease Major depressive disorder , major psychiatric disorder Use acetylcholinesterase inhibitor memantine treatment Alzheimer 's disease within 8 week prior enrollment Impaired vision and/or hear make cognitive testing difficult</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer Type</keyword>
	<keyword>Alzheimer Disease</keyword>
</DOC>